Pharmaceutical News RSS Feed - Pharmaceutical News

Prexton closes €8.7 million in Series A financing to develop treatments for Parkinson’s disease

Prexton closes €8.7 million in Series A financing to develop treatments for Parkinson’s disease

Prexton Therapeutics, a biopharmaceutical company developing novel therapeutic compounds for the treatment of CNS conditions including Parkinson’s disease, today announces the closing of a Series A financing of €8.7 million ($10 million) co-led by Sunstone Capital and Ysios Capital. [More]
Tolero's alvocidib receives EMA orphan drug designation for treatment of AML patients

Tolero's alvocidib receives EMA orphan drug designation for treatment of AML patients

Tolero Pharmaceuticals, Inc., a clinical-stage company developing treatments for serious hematological diseases, today announced that the European Medicines Agency has granted orphan drug designation for alvocidib for the treatment of patients with acute myeloid leukemia (AML). [More]
Remsima (infliximab) now available in Europe for treatment of autoimmune diseases

Remsima (infliximab) now available in Europe for treatment of autoimmune diseases

Celltrion Healthcare has today announced the launch of Remsima (infliximab) in 12 European markets: Austria, Belgium, Denmark, France, Germany, Greece, Italy, Luxembourg, the Netherlands, Spain, Sweden and the UK. [More]
Sanofi announces FDA approval of Toujeo insulin to improve glycemic control in people with diabetes

Sanofi announces FDA approval of Toujeo insulin to improve glycemic control in people with diabetes

Sanofi announced today that the U.S. Food and Drug Administration approved Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL), a once-daily long-acting basal insulin, to improve glycemic control in adults living with type 1 and type 2 diabetes. Toujeo is expected to be available in the U.S. at the beginning of Q2 2015. [More]
Gates Foundation awards $2.5 million to support development of vaccine-filled microneedles

Gates Foundation awards $2.5 million to support development of vaccine-filled microneedles

The Georgia Institute of Technology and Micron Biomedical have been awarded $2.5 million in grants from the Bill & Melinda Gates Foundation to advance the development of dissolvable microneedle patches for polio immunization. The patches will be studied to evaluate their potential role as part of the worldwide efforts to eradicate polio. [More]
AR-V7 status does not affect response to taxane chemotherapy in patients with mCRPC

AR-V7 status does not affect response to taxane chemotherapy in patients with mCRPC

Findings from a small prospective study suggest that androgen receptor V7 (or AR-V7) status does not significantly affect response to taxane chemotherapy in men with metastatic castration-resistant prostate cancer (mCRPC). Treatment outcomes were largely similar for the 17 patients with AR-V7-positive prostate cancer and the 20 patients with AR-V7-negative disease included in this analysis. [More]
Researchers develop revolutionary approach to treat drug-resistant tumors

Researchers develop revolutionary approach to treat drug-resistant tumors

In greater than 90 percent of cases in which treatment for metastatic cancer fails, the reason is that the cancer is resistant to the drugs being used. To treat drug-resistant tumors, doctors typically use multiple drugs simultaneously, a practice called combination therapy. [More]
Study: Gene variant linked to increased risk of vincristine-induced peripheral neuropathy in children

Study: Gene variant linked to increased risk of vincristine-induced peripheral neuropathy in children

Children with acute lymphoblastic leukemia who had a certain gene variant experienced a higher incidence and severity of peripheral neuropathy after receiving treatment with the cancer drug vincristine, according to a study in the February 24 issue of JAMA. [More]
Researchers find that new targeted drugs can attack weak spots in cancer cells

Researchers find that new targeted drugs can attack weak spots in cancer cells

Scientists have identified weak spots in cancer cells that could be targeted and attacked by new precision drugs. [More]
Indiana University study reveals connection between mussels and muscles

Indiana University study reveals connection between mussels and muscles

An Indiana University study has revealed that there may be a greater connection between mussels and muscles than previously thought. [More]
Study shows how financial incentives can influence some HIV-positive patients in clinical settings

Study shows how financial incentives can influence some HIV-positive patients in clinical settings

A new study by the HIV Prevention Trials Network shows that some HIV-positive patients were motivated by financial incentives to take their HIV antiretroviral therapy (ART) medication regularly and maintain control of their HIV - enhancing their own health benefits and reducing the chance of passing the virus on to others. [More]
Medicago receives task order from HHS BARDA to manufacture anti-Ebola virus monoclonal antibodies

Medicago receives task order from HHS BARDA to manufacture anti-Ebola virus monoclonal antibodies

Medicago, a leading company in the development and production of plant-based vaccines and therapeutics, announced today that it has received a task order from the Biomedical Advanced Research and Development Authority at the U.S. Department of Health and Human Services for three anti-Ebola virus monoclonal antibodies (mAbs) with expected performance comparable to that of ZMapp, from Mapp Biopharmaceutical. [More]

MPP, MSD sign licensing agreement for paediatric formulations of raltegravir

The Medicines Patent Pool announced a licence today with MSD, known as Merck in the United States and Canada, for paediatric formulations of raltegravir, a key medicine approved for children living with HIV four weeks of age and older. [More]
People who exhibit resistance to aspirin may be at risk of more severe strokes

People who exhibit resistance to aspirin may be at risk of more severe strokes

People who exhibit a resistance to aspirin may be more likely to have more severe strokes than people who still respond to the drug, according to a study released today that will be presented at the American Academy of Neurology's 67th Annual Meeting in Washington, DC, April 18 to 25, 2015. [More]
Study suggests that antibiotics can induce potentially dangerous biofilm formation

Study suggests that antibiotics can induce potentially dangerous biofilm formation

Most people have taken an antibiotic to treat a bacterial infection. Now researchers from the University of North Carolina at Chapel Hill and the University of San Diego, La Jolla, reveal that the way we often think about antibiotics - as straightforward killing machines - needs to be revised. [More]
Researchers find key protein critical to the success of common anti-platelet drug Plavix

Researchers find key protein critical to the success of common anti-platelet drug Plavix

Researchers at the UNC School of Medicine have found that the blood platelet protein Rasa3 is critical to the success of the common anti-platelet drug Plavix, which breaks up blood clots during heart attacks and other arterial diseases. [More]
MD Anderson researchers find way to predict patients who may respond to BRAF inhibitors

MD Anderson researchers find way to predict patients who may respond to BRAF inhibitors

Powerful drugs known as BRAF-inhibitors have been crucial for melanoma patients, saving lives through their ability to turn off the BRAF protein's power to spur cancer cell growth. [More]
LSU Health New Orleans finalizes deal with CB BioSciences

LSU Health New Orleans finalizes deal with CB BioSciences

The Office of Technology Management at LSU Health New Orleans has finalized a deal with CB BioSciences, Inc., a startup drug development company to build a platform around the intellectual property portfolio of Chu Chen, PhD, LSU Health New Orleans Professor of Neuroscience. [More]
Rigel, Bristol-Myers Squibb partner to develop, commercialize TGF beta receptor kinase inhibitors

Rigel, Bristol-Myers Squibb partner to develop, commercialize TGF beta receptor kinase inhibitors

Rigel Pharmaceuticals, Inc. and Bristol-Myers Squibb Company today announced that they have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies based on Rigel's extensive portfolio of small molecule TGF beta receptor kinase inhibitors. [More]
CannTrust receives Health Canada approval to produce, distribute medical cannabis in Canada

CannTrust receives Health Canada approval to produce, distribute medical cannabis in Canada

CannTrust Inc., a privately held, wholly-owned Canadian company, has been approved by Health Canada as a Licensed Producer and distributor of medical cannabis in Canada, under the Marihuana for Medical Purposes Regulations. [More]